In this nationwide phase 3-4 cluster-randomised , double-blind trial , children younger than 19 months were randomly assigned to receive PHiD-CV10 in 52 of 78 clusters or hepatitis B or A vaccine as control in 26 clusters according to three plus one or two plus one schedules ( infants younger than 7 months ) or catch-up schedules ( children aged 7-18 months ) .